Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer.
Giandomenico RovielloF U ConterE MiniD GeneraliM TraversiniD LavacchiS NobiliN SobhaniPublished in: Cancer chemotherapy and pharmacology (2019)
Gastric cancer (GC) is the third cause of cancer-related death worldwide. Patients with unresectable GC can be treated with chemotherapy such as paclitaxel, which is a microtubule stabilizer. The use of nanoparticle albumin-bound paclitaxel (nab-ptx) avoids hypersensitivity reactions due to the absence of solvent needed to dissolve paclitaxel and it can be administered at higher doses. The ABSOLUTE randomized phase-3 clinical trial showed the non-inferiority of the nab-ptx used every week compared to the solvent-based paclitaxel used every week. This review describes the current advancements of the use of nab-ptx in GC in preclinical and clinical study investigations. The possibility of combining nab-ptx with other medications to improve response of patients to their specific molecular needs will also be debated.
Keyphrases
- advanced non small cell lung cancer
- clinical trial
- double blind
- chemotherapy induced
- placebo controlled
- end stage renal disease
- newly diagnosed
- open label
- ejection fraction
- locally advanced
- chronic kidney disease
- phase ii
- phase iii
- prognostic factors
- randomized controlled trial
- radiation therapy
- study protocol
- gas chromatography
- stem cells
- patient reported outcomes
- epidermal growth factor receptor
- drug induced
- single molecule
- combination therapy
- high resolution
- rectal cancer
- solid phase extraction